Rimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. . Its main avenue of effect is reduction in appetite. Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world.
Rimonabant hydrochloride, is a new weight loss drug, not only can lose weight, but also lower blood pressure, cholesterol and blood sugar. And it is also the first drug in a new class of selective canna binoid type 1 receptor antagonists, is showing promise in clinical trials for the treatment of obesity and related metabolic risk factors, in addition to tobacco dependence, when lost significant body weight when treated with rimonabant 20 mg for a year.
